Literature DB >> 35726607

Diagnosis, Management, and Future Control of Cholera.

Fahima Chowdhury1,2, Allen G Ross3, Md Taufiqul Islam1,2, Nigel A J McMillan2, Firdausi Qadri1.   

Abstract

Cholera, caused by Vibrio cholerae, persists in developing countries due to inadequate access to safe water, sanitation, and hygiene. There are approximately 4 million cases and 143,000 deaths each year due to cholera. The disease is transmitted fecally-orally via contaminated food or water. Severe dehydrating cholera can progress to hypovolemic shock due to the rapid loss of fluids and electrolytes, which requires a rapid infusion of intravenous (i.v.) fluids. The case fatality rate exceeds 50% without proper clinical management but can be less than 1% with prompt rehydration and antibiotics. Oral cholera vaccines (OCVs) serve as a major component of an integrated control package during outbreaks or within zones of endemicity. Water, sanitation, and hygiene (WaSH); health education; and prophylactic antibiotic treatment are additional components of the prevention and control of cholera. The World Health Organization (WHO) and the Global Task Force for Cholera Control (GTFCC) have set an ambitious goal of eliminating cholera by 2030 in high-risk areas.

Entities:  

Keywords:  Vibrio cholerae; WaSH; oral cholera vaccine; treatment

Mesh:

Substances:

Year:  2022        PMID: 35726607      PMCID: PMC9491185          DOI: 10.1128/cmr.00211-21

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   50.129


  132 in total

1.  Molecular characterization of a new variant of toxin-coregulated pilus protein (TcpA) in a toxigenic non-O1/Non-O139 strain of Vibrio cholerae.

Authors:  B Nandi; R K Nandy; A C Vicente; A C Ghose
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 2.  Current and future cholera vaccines.

Authors:  Hanif Shaikh; Julia Lynch; Jerome Kim; Jean-Louis Excler
Journal:  Vaccine       Date:  2019-12-24       Impact factor: 3.641

3.  Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial.

Authors:  Firdausi Qadri; Mohammad Ali; Fahima Chowdhury; Ashraful Islam Khan; Amit Saha; Iqbal Ansary Khan; Yasmin A Begum; Taufiqur R Bhuiyan; Mohiul Islam Chowdhury; Md Jasim Uddin; Jahangir A M Khan; Atique Iqbal Chowdhury; Anisur Rahman; Shah Alam Siddique; Muhammad Asaduzzaman; Afroza Akter; Arifuzzaman Khan; Young Ae You; Ashraf Uddin Siddik; Nirod Chandra Saha; Alamgir Kabir; Baizid Khoorshid Riaz; Shwapon Kumar Biswas; Farzana Begum; Leanne Unicomb; Stephen P Luby; Alejandro Cravioto; John D Clemens
Journal:  Lancet       Date:  2015-07-09       Impact factor: 79.321

4.  An overview of VaxchoraTM, a live attenuated oral cholera vaccine.

Authors:  Tarun Saluja; Vijayalaxmi V Mogasale; Jean-Louis Excler; Jerome H Kim; Vittal Mogasale
Journal:  Hum Vaccin Immunother       Date:  2019-09-20       Impact factor: 3.452

Review 5.  The incubation period of cholera: a systematic review.

Authors:  Andrew S Azman; Kara E Rudolph; Derek A T Cummings; Justin Lessler
Journal:  J Infect       Date:  2012-11-29       Impact factor: 6.072

Review 6.  Meeting cholera's challenge to Haiti and the world: a joint statement on cholera prevention and care.

Authors:  Paul Farmer; Charles Patrick Almazor; Emily T Bahnsen; Donna Barry; Junior Bazile; Barry R Bloom; Niranjan Bose; Thomas Brewer; Stephen B Calderwood; John D Clemens; Alejandro Cravioto; Eddy Eustache; Gregory Jérôme; Neha Gupta; Jason B Harris; Howard H Hiatt; Cassia Holstein; Peter J Hotez; Louise C Ivers; Vanessa B Kerry; Serena P Koenig; Regina C Larocque; Fernet Léandre; Wesler Lambert; Evan Lyon; John J Mekalanos; Joia S Mukherjee; Cate Oswald; Jean-William Pape; Anany Gretchko Prosper; Regina Rabinovich; Maxi Raymonville; Jean-Renold Réjouit; Laurence J Ronan; Mark L Rosenberg; Edward T Ryan; Jeffrey D Sachs; David A Sack; Claude Surena; Arjun A Suri; Ralph Ternier; Matthew K Waldor; David Walton; Jonathan L Weigel
Journal:  PLoS Negl Trop Dis       Date:  2011-05-31

7.  Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial.

Authors:  Dipika Sur; Suman Kanungo; Binod Sah; Byomkesh Manna; Mohammad Ali; Allison M Paisley; Swapan K Niyogi; Jin Kyung Park; Banawarilal Sarkar; Mahesh K Puri; Deok Ryun Kim; Jacqueline L Deen; Jan Holmgren; Rodney Carbis; Raman Rao; Thu Van Nguyen; Seung Hyun Han; Stephen Attridge; Allan Donner; Nirmal K Ganguly; Sujit K Bhattacharya; G Balakrish Nair; John D Clemens; Anna Lena Lopez
Journal:  PLoS Negl Trop Dis       Date:  2011-10-18

8.  Pregnancy Outcomes after a Mass Vaccination Campaign with an Oral Cholera Vaccine in Guinea: A Retrospective Cohort Study.

Authors:  Lise Grout; Isabel Martinez-Pino; Iza Ciglenecki; Sakoba Keita; Alpha Amadou Diallo; Balla Traore; Daloka Delamou; Oumar Toure; Sarala Nicholas; Barbara Rusch; Nelly Staderini; Micaela Serafini; Rebecca F Grais; Francisco J Luquero
Journal:  PLoS Negl Trop Dis       Date:  2015-12-29

9.  Parenteral Vaccination with a Cholera Conjugate Vaccine Boosts Vibriocidal and Anti-OSP Responses in Mice Previously Immunized with an Oral Cholera Vaccine.

Authors:  Aklima Akter; Meagan Kelly; Richelle C Charles; Jason B Harris; Stephen B Calderwood; Taufiqur R Bhuiyan; Rajib Biswas; Peng Xu; Pavol Kováč; Firdausi Qadri; Edward T Ryan
Journal:  Am J Trop Med Hyg       Date:  2021-04-19       Impact factor: 2.345

Review 10.  The Impact of Water, Sanitation and Hygiene Interventions to Control Cholera: A Systematic Review.

Authors:  Dawn L Taylor; Tanya M Kahawita; Sandy Cairncross; Jeroen H J Ensink
Journal:  PLoS One       Date:  2015-08-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.